FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3024892376> ?p ?o ?g. }

• W3024892376 endingPage "162" @default.
• W3024892376 startingPage "149" @default.
• W3024892376 abstract "To compare the efficacy of platinum- and non-platinum-based regimens as first-line treatment for advanced triple-negative breast cancer (TNBC) and analyze the relationship between their efficacy and BRCA gene status.Retrospectively analyze clinical data of 220 patients diagnosed pathologically with advanced TNBC and treated at the Department of Breast Oncology, Peking University Cancer Hospital from 2013 to 2018 and evaluate the efficacy of chemotherapy. A total of 114 patients had BRCA1/2 gene tested by next generation sequencing (NGS) using peripheral blood, and we analyzed the correlation between their efficacy and BRCA1/2 gene status.Non-platinum-based chemotherapy (NPCT) was administered to 129 and platinum-based chemotherapy (PBCT) to 91 study patients. The clinical benefit rate (CBR) and median progression-free survival (PFS) were not statistically different between NPCT and PBCT groups. The median overall survival (OS) was 30.0 and 22.5 months for PBCT and NPCT group, respectively [P=0.090, hazard ratios (HR)=0.703]. BRCA status was assessed in 114 patients, 14 of whom had deleterious germline BRCA1/2 (gBRCA) mutations (seven in each group). In PBCT group, the CBR was 85.7% and 35.1% for patients with and without deleterious gBRCA mutations, respectively (P=0.039). The median PFS were 14.9 and 5.3 months and median OS were 26.5 and 15.5 months for patients with and without deleterious gBRCA mutations, respectively (P=0.001, P=0.161, respectively). Patients in PBCT group had significantly greater rates of grade 3-4 anemia (5.5%vs. 0%) and thrombocytopenia (8.8% vs. 0%), whereas palmar-plantar erythrodysesthesia (12.4% vs. 0%) and peripheral neuropathy (8.6% vs. 1.1%) occurred more frequently in NPCT group.Platinum-based regimens are more effective in patients with deleterious gBRCA mutations, but no difference in patients without BRCA gene mutations, so non-platinum is an option in patients without BRCA gene mutations considering the toxicity and side effect. And we recommend that patients with advanced TNBC should have BRCA gene test." @default.
• W3024892376 created "2020-05-21" @default.
• W3024892376 creator A5003088149 @default.
• W3024892376 creator A5006304214 @default.
• W3024892376 creator A5010465278 @default.
• W3024892376 creator A5015806797 @default.
• W3024892376 creator A5032035596 @default.
• W3024892376 creator A5035927781 @default.
• W3024892376 creator A5036990231 @default.
• W3024892376 creator A5040847846 @default.
• W3024892376 creator A5045763537 @default.
• W3024892376 creator A5060589194 @default.
• W3024892376 creator A5065460631 @default.
• W3024892376 creator A5067866708 @default.
• W3024892376 creator A5069105482 @default.
• W3024892376 date "2020-01-01" @default.
• W3024892376 modified "2023-10-13" @default.
• W3024892376 title "Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing" @default.
• W3024892376 cites W1984431444 @default.
• W3024892376 cites W2012946235 @default.
• W3024892376 cites W2027260716 @default.
• W3024892376 cites W2029151927 @default.
• W3024892376 cites W2051978340 @default.
• W3024892376 cites W2075894019 @default.
• W3024892376 cites W2096027508 @default.
• W3024892376 cites W2100766868 @default.
• W3024892376 cites W2101904315 @default.
• W3024892376 cites W2110137106 @default.
• W3024892376 cites W2113382133 @default.
• W3024892376 cites W2118410764 @default.
• W3024892376 cites W2128740744 @default.
• W3024892376 cites W2142226415 @default.
• W3024892376 cites W2145694567 @default.
• W3024892376 cites W2170602872 @default.
• W3024892376 cites W2170856503 @default.
• W3024892376 cites W2583034197 @default.
• W3024892376 cites W2593506747 @default.
• W3024892376 cites W2604876648 @default.
• W3024892376 cites W2607840379 @default.
• W3024892376 cites W2737863823 @default.
• W3024892376 cites W2767834636 @default.
• W3024892376 cites W2773888891 @default.
• W3024892376 cites W2782319349 @default.
• W3024892376 cites W2791090958 @default.
• W3024892376 cites W2792164419 @default.
• W3024892376 cites W2801956643 @default.
• W3024892376 cites W2805391348 @default.
• W3024892376 cites W2808021743 @default.
• W3024892376 cites W2886489770 @default.
• W3024892376 cites W2888491849 @default.
• W3024892376 cites W2889911732 @default.
• W3024892376 cites W2897926526 @default.
• W3024892376 cites W4241563152 @default.
• W3024892376 doi "https://doi.org/10.21147/j.issn.1000-9604.2020.02.03" @default.
• W3024892376 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7219102" @default.
• W3024892376 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32410793" @default.
• W3024892376 hasPublicationYear "2020" @default.
• W3024892376 type Work @default.
• W3024892376 sameAs 3024892376 @default.
• W3024892376 citedByCount "12" @default.
• W3024892376 countsByYear W30248923762020 @default.
• W3024892376 countsByYear W30248923762021 @default.
• W3024892376 countsByYear W30248923762022 @default.
• W3024892376 countsByYear W30248923762023 @default.
• W3024892376 crossrefType "journal-article" @default.
• W3024892376 hasAuthorship W3024892376A5003088149 @default.
• W3024892376 hasAuthorship W3024892376A5006304214 @default.
• W3024892376 hasAuthorship W3024892376A5010465278 @default.
• W3024892376 hasAuthorship W3024892376A5015806797 @default.
• W3024892376 hasAuthorship W3024892376A5032035596 @default.
• W3024892376 hasAuthorship W3024892376A5035927781 @default.
• W3024892376 hasAuthorship W3024892376A5036990231 @default.
• W3024892376 hasAuthorship W3024892376A5040847846 @default.
• W3024892376 hasAuthorship W3024892376A5045763537 @default.
• W3024892376 hasAuthorship W3024892376A5060589194 @default.
• W3024892376 hasAuthorship W3024892376A5065460631 @default.
• W3024892376 hasAuthorship W3024892376A5067866708 @default.
• W3024892376 hasAuthorship W3024892376A5069105482 @default.
• W3024892376 hasBestOaLocation W30248923761 @default.
• W3024892376 hasConcept C121608353 @default.
• W3024892376 hasConcept C126322002 @default.
• W3024892376 hasConcept C143998085 @default.
• W3024892376 hasConcept C207103383 @default.
• W3024892376 hasConcept C2776694085 @default.
• W3024892376 hasConcept C2778248108 @default.
• W3024892376 hasConcept C2780110267 @default.
• W3024892376 hasConcept C2780194787 @default.
• W3024892376 hasConcept C44249647 @default.
• W3024892376 hasConcept C530470458 @default.
• W3024892376 hasConcept C71924100 @default.
• W3024892376 hasConceptScore W3024892376C121608353 @default.
• W3024892376 hasConceptScore W3024892376C126322002 @default.
• W3024892376 hasConceptScore W3024892376C143998085 @default.
• W3024892376 hasConceptScore W3024892376C207103383 @default.
• W3024892376 hasConceptScore W3024892376C2776694085 @default.
• W3024892376 hasConceptScore W3024892376C2778248108 @default.
• W3024892376 hasConceptScore W3024892376C2780110267 @default.
• W3024892376 hasConceptScore W3024892376C2780194787 @default.

• next